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DOI 10.1016/j.ccr.2011.04.004SUMMARYAnaplastic lymphoma kinase (ALK) is a tyrosine kinase that is constitutively activated in certain cancers,
following gene alterations such as chromosomal translocation, amplification, or point mutation. Here, we
identified CH5424802, a potent, selective, and orally available ALK inhibitor with a unique chemical scaffold,
showing preferential antitumor activity against cancers with gene alterations of ALK, such as nonsmall cell
lung cancer (NSCLC) cells expressing EML4-ALK fusion and anaplastic large-cell lymphoma (ALCL) cells
expressing NPM-ALK fusion in vitro and in vivo. CH5424802 inhibited ALK L1196M, which corresponds to
the gatekeeper mutation conferring common resistance to kinase inhibitors, and blocked EML4-ALK
L1196M-driven cell growth. Our results support the potential for clinical evaluation of CH5424802 for the
treatment of patients with ALK-driven tumors.INTRODUCTION
Genetic alterations, such as point mutation, chromosomal trans-
location, and gene amplification, have been identified in various
cancers by molecular profiling studies. In clinical studies the
remarkable success of targeted protein kinase inhibitors has
highlighted the importance of identifying genotype-specific
subsets of patients to guide the appropriate selection of targeted
therapies. On the other hand, certain factors limit the efficacy of
cancer therapies owing to a narrow therapeutic index caused by
blocking of multiple kinases related to the regulation of normal
cell growth. A second-generation BCR-ABL inhibitor, nilotinib,
is amore potent and selective inhibitor of BCR-ABL than imatinib
(Weisberg et al., 2005). A recent clinical trial revealed that niloti-
nib was superior to imatinib against newly diagnosed BCR-ABL-
positive chronic myelogenous leukemia (CML) (Saglio et al.,
2010), suggesting that more potent and selective kinase inhibi-
tors needed to be developed in order to achieve higher efficacy
and safety.Significance
The recent development of targeted protein kinase inhibitors
certain factors limit the efficacy of cancer therapies, such as
kinases, and the emergence of resistantmutants. CH5424802 h
tive properties, and potential antitumor activity against the ga
confirmed in tumor cells isolated from a patient with NSCLC w
(crizotinib). Potent ALK inhibitors effective against the gateke
ment for patients with ALK-driven tumors.Acquired resistance to kinase inhibitors is one of the most
serious problems in long-term cancer treatment; this is caused
by various mechanisms, such as gene alterations of the target
molecules or other gene alterations. In the majority of cases, it
results from the selection of cancer cells with point mutations
in the kinase catalytic domain of target genes such as ABL or
EGFR (Branford et al., 2002; Pao et al., 2005). Among the point
mutations in the kinase domain, the gatekeeper-residue muta-
tion is known to be commonly involved in resistance to kinase
inhibitors. Based on a recent structural analysis of the kinase
domain, AP24534was shown to inhibit the BCR-ABL T315I gate-
keeper mutant (O’Hare et al., 2009). Furthermore, irreversible
EGFR inhibitors have been shown to overcome the acquired
resistance by the T790M-resistant mutation of EGFR (Zhou
et al., 2009; Sos et al., 2010). Thus, kinase inhibitors retaining
the inhibitory potency against the gatekeeper mutants would
confer various advantages in longer-term cancer treatment.
EML4-ALK has been identified as a fusion oncogene in non-
small cell lung cancer (NSCLC) (Soda et al., 2007). Thehas provided opportunities in cancer treatment. However,
a narrow therapeutic index caused by inhibition of multiple
as been demonstrated to be an ALK inhibitor with high selec-
tekeeper mutant L1196M in EML4-ALK, which was clinically
ho was refractory to the c-MET/ALK inhibitor, PF-02341066
eper mutants may offer clinical advantages in cancer treat-
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CH5424802 Can Block Gatekeeper Mutant of ALKtumorigenic potential of EML4-ALKwas subsequently confirmed
using a transformation assay via the subcutaneous (s.c.) injec-
tion of transfected 3T3 fibroblasts into mice (Soda et al., 2007)
and the transgenic mice (Soda et al., 2008). EML4-ALK positivity
was shown to be associated with resistance to EGFR tyrosine
kinase inhibitors among patients with metastatic NSCLC (Rodig
et al., 2009). Moreover, multiple variants of EML4-ALK (Choi
et al., 2008; Takeuchi et al., 2008) and other oncokinase fusions
such as KIF5B-ALK (Takeuchi et al., 2009) have also been iden-
tified in NSCLC. In addition to NSCLC, anaplastic lymphoma
kinase (ALK) fusion proteins have been identified in anaplastic
large-cell lymphoma (ALCL) (Morris et al., 1994) and inflamma-
tory myofibroblastic tumors (IMTs) (Griffin et al., 1999). Gene
amplification or point mutation of ALK was demonstrated to be
in the oncogenesis of neuroblastoma (Chen et al., 2008; George
et al., 2008; Janoueix-Lerosey et al., 2008; Mosse´ et al., 2008).
Because the growth of these tumors is strongly addicted to
ALK activity, suppression of ALK could be a potent therapeutic
strategy for patients with gene alterations of ALK. Small-mole-
cule ALK inhibitors have not yet been approved as anticancer
agents. PF-02341066 (Christensen et al., 2007), an inhibitor of
c-MET and ALK, showed a high response rate in patients with
NSCLC with ALK rearrangement in clinical trial (Kwak et al.,
2010), and it is currently under phase III clinical development.
Meanwhile, a recent report described the identification of
EML4-ALK C1156Y and L1196M mutations by genetic analysis
using a pleural-effusion specimen from a patient with NSCLC
who relapsed after a partial response to PF-02341066 in clinical
trial, suggesting that L1196M and C1156Y mutation confer clin-
ical resistance to ALK inhibitors (Choi et al., 2010). Additionally,
F1174L mutation was identified as one of the causes of
PF-02341066 resistance in a patient with an IMT harboring an
RANBP2-ALK translocation who progressed while on
PF-02341066 (Sasaki et al., 2010). Thus, the development of
ALK inhibitors with effectiveness to resistant mutants would be
needed.
RESULTS
Potent and Selective Inhibition of ALK Activity
of CH5424802
In order to differentiate from other described ALK inhibitors, we
focused on identifying a more selective ALK inhibitor. We have
performed high-throughput inhibitor screening against multiple
cancer-related tyrosine kinase targets and obtained several
hits with previously unreported chemical scaffolds. Among the
derivatives we found a lead compound that strongly inhibits
ALK; subsequently, we intensively modified and improved its
kinase selectivity and pharmacokinetics profile. Finally, we iden-
tified a benzo[b]carbazole derivative, CH5424802, as a potent,
selective, and orally available ALK inhibitor (Figure 1A). In cell-
free assays the IC50 of CH5424802 for enzyme activity of ALK
was 1.9 nM (Table 1; see Table S1 available online); the dissoci-
ation constant (KD) value for ALK in an ATP-competitive manner
was 2.4 nM using a competition-binding assay (Ambit). The
inhibitory activity for two hot spot-activating mutations in neuro-
blastoma, F1174L and R1275Q, was comparable to that for wild-
type ALK (Table 1). To explore the kinase selectivity of
CH5424802, its inhibitory activity on various kinases was680 Cancer Cell 19, 679–690, May 17, 2011 ª2011 Elsevier Inc.measured, revealing weak or no inhibition against 24 protein
kinases other than ALK (Table 1). Furthermore, using Ambit’s
kinase screening platform, CH5424802 was profiled against
402 kinases including the mutated kinases. Only three kinases,
ALK, GAK, and LTK, showed more than 50% inhibition at
10 nM, which corresponds to approximately 5-fold higher
concentration of IC50 values for ALK (Table S2). LTK is known
to show greatest sequence similarity to ALK (Iwahara et al.,
1997). In cellular phosphorylation assays, CH5424802 could
prevent autophosphorylation of ALK in NCI-H2228 NSCLC cells
expressing EML4-ALK (Figure 1B), and it also resulted in
substantial suppression of phosphorylation of STAT3 and AKT,
but not of ERK1/2. However, inhibition of these phosphorylations
was not observed in ALK fusion-negative A549 cell line
(Figure S1A).
Selective Antitumor Activity in ALK-Positive Cancers
In NSCLC, EML4-ALK fusion has been shown to be mutually
exclusive with EGFR or KRAS mutations (Inamura et al., 2008).
It has also been reported that EGFR tyrosine kinase inhibitors
have high clinical efficacy as therapeutic agents for NSCLCs
with EGFR mutations (Pao et al., 2004). Using NSCLC cell lines
with distinct genotypes, we tested the antiproliferative effects
of CH5424802. CH5424802 was preferentially efficacious
against NCI-H2228 cells expressing EML4-ALK, but not ALK
fusion-negative NSCLC cell lines, including HCC827 cells
(EGFR exon 19 deletion), A549 cells (KRAS mutant), or NCI-
H522 cells (EGFR wild-type, KRAS wild-type, and ALK wild-
type) in monolayer culture (Figure 1C; Table S3). Similar results
were obtained under three-dimensional (3D) spheroid culture
conditions (NCI-H2228, IC50 = 33 nM) (Figure 1D). CH5424802
could induce an apoptotic marker—caspase-3/7-like activa-
tion—in NCI-H2228 spheroid cells (Figure 1E), indicating the
involvement of apoptosis induction in the antitumor activity of
CH5424802. The caspase-3/7-like activation was also observed
in a treatment of other ALK inhibitors, PF-02341066 and NVP-
TAE684, under spheroid culture conditions (Figure S1B). Addi-
tionally, we confirmed that EGFR mutant HCC827 cells showed
higher sensitivity to the EGFR kinase inhibitor gefitinib, but not to
CH5424802 (Figure 1D, middle panel). To evaluate the sensitivity
of cell lines with gene alterations of ALK other than NSCLC, we
performed in vitro cell growth inhibition assays using human
lymphoma and neuroblastoma cell lines. CH5424802 inhibited
the growth of two lymphoma lines, KARPAS-299 and SR, with
NPM-ALK fusion protein but did not affect the growth of an
HDLM-2 lymphoma line without ALK fusion (Table S3). Among
neuroblastoma lines, NB-1 cells contain amplified ALK (Chen
et al., 2008), whereas KELLY cells harbor the ALK-activating
F1174L point mutation (George et al., 2008). These two neuro-
blastoma lines with genetic alterations of ALK were sensitive to
CH5424802, but the wild-type line SK-N-FI was not (Table S3).
To further confirm the kinase selectivity in cells, we examined
the sensitivity of cell lines with alterations in kinase genes, which
are susceptible to the corresponding kinase inhibitors (e.g.,
c-MET inhibitors for c-MET gene amplification). CH5424802
was not efficacious against c-MET-, FGFR2-, or ERBB2-ampli-
fied cancer cell lines (Table S3). On the other hand, c-MET-
amplified cancer cell lines were reported to show high sensitivity
to a c-MET inhibitor (Smolen et al., 2006). These results indicated
Figure 1. Selective Antitumor Activity in ALK-Positive NSCLC Cell Lines
(A) Chemical structure of CH5424802.
(B) Inhibition of ALK phosphorylation and signal transduction by CH5424802. NCI-H2228 cells were treated with CH5424802 for 2 hr at the indicated concen-
trations. ALK, STAT3, phosphorylated STAT3 (Tyr 705), AKT, phosphorylated AKT (Ser 473), ERK1/2, and phosphorylated ERK1/2 (Thr 202/Tyr 204) were
detected by immunoblot analysis using antibodies to each of them. For phosphorylated ALK detection, cell lysates were immunoprecipitated with anti-phos-
photyrosine antibody. The immunoprecipitants were then collected with Protein G Sepharose and subjected to immunoblot analysis using an anti-ALK antibody.
(C) Cells were seeded in a monolayer culture and incubated overnight, and then treated with various concentrations of CH5424802 for 5 days. The viable cells
were measured by the CellTiter-Glo Luminescent Cell Viability Assay. Data are shown as mean ± SD (n = 3).
(D) Cells were seeded on spheroid plates and incubated overnight, and then treatedwith CH5424802 or gefitinib for 5 days. The viable cells weremeasured by the
CellTiter-Glo Luminescent Cell Viability Assay. Data are shown as mean ± SD (n = 3). conc, concentration.
(E) Cells were seeded on spheroid plates and incubated overnight, and then treated with CH5424802 for 48 hr. Caspase 3/7 activation was measured by using
Caspase-Glo3/7 assay kit. Data were calculated by dividing by the number of viable cells, and shown as mean ± SD (n = 3).
See also Figure S1 and Tables S1 and S2.
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CH5424802 Can Block Gatekeeper Mutant of ALKselective antitumor activity of CH5424802 against various
cancer cells with genetic alterations of ALK.
We next tested the efficacy of CH5424802 using a mouse
xenograft model. In the NCI-H2228 model, once-daily oral
administration of CH5424802 resulted in dose-dependent tumor
growth inhibition (ED50 = 0.46 mg/kg) and tumor regression (Fig-
ure 2A). Treatment of 20 mg/kg CH5424802 showed rapid tumor
regression (168% tumor growth inhibition; p < 0.001), the tumor
volume in any mouse was <30mm3 after 11 days of treatment (at
day 28), a potent antitumor effect was maintained, and tumor
regrowth did not occur throughout the 4-week drug-free period.
In pharmacokinetic studies we determined the half-life (8.6 hr)
and the oral bioavailability (70.8%) of CH5424802 in mice. At
a repeated dose of 6 mg/kg, the mean plasma levels reached
1707, 1455, and 317 nM at 2, 7, and 24 hr post-dose, respec-
tively. The plasma concentrations substantially exceed the
in vitro IC50 values for NCI-H2228 (Figures 1C and 1D). At any
dose level, no differences in body weight or gross signs oftoxicity were observed between control- and CH5424802-
treated mice. In contrast, CH5424802 had practically no anti-
tumor effect in the xenograft model of A549, an NSCLC cell
line that does not express ALK fusions (Figure 2A). Immunohisto-
chemical assays demonstrated that the levels of phosphorylated
ALK are decreased in the xenograft tumors harboring EML4-ALK
after a single dose of CH5424802 (Figure 2B). In order to evaluate
maximum efficacy, we conducted an efficacy study at 60 mg/kg
against larger tumors (from an average tumor size of 340–
350 mm3) during long-term observation because the exposure
of CH5424802 in mice had nearly peaked at 60 mg/kg. After
administration of CH5424802 at 60 mg/kg for 3 weeks, tumor
regrowth did not occur for 4 weeks (Figure 2C). There was no
body weight loss, no significant changes in peripheral white
blood cell and red blood cell counts, no elevations of aspartate
aminotransferase (AST) and alanine aminotransferase (ALT),
and no substantial changes in electrolytes (Na, K, and Cl) in
mice at dose levels up to 60 mg/kg (Table S4). SimilarCancer Cell 19, 679–690, May 17, 2011 ª2011 Elsevier Inc. 681
Table 1. Enzyme Inhibitory Activity of CH5424802 on Various
Kinases
Tyr Kinase IC50 (nM) Ser/Thr Kinase IC50 (nM)
ALK 1.9 AKT1 >5000
ALK F1174L 1.0 AKT2 >5000
ALK R1275Q 3.5 AKT3 >5000
INSR 550 Aurora A >5000
KDR 1400 CDK1 >5000
ABL >5000 CDK2 >5000
EGFR >5000 MEK1 >5000
FGFR2 >5000 PKA >5000
HER2 >5000 PKCa >5000
IGF1R >5000 PKCb1 >5000
JAK1 >5000 PKCb2 >5000
KIT >5000 Raf-1 >5000
MET >5000
PDGFRb >5000
SRC >5000
The in vitro kinase inhibitory assays in the presence of CH5424802 were
carried out according to the Experimental Procedures. See also Table S1.
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CH5424802 Can Block Gatekeeper Mutant of ALKexperiments were performed in models generated by implanta-
tion of KARPAS-299 ALCL cells and NB-1 neuroblastoma cells.
In both the models, administration of CH5424802 led to tumor
growth inhibition and tumor regression (Figure 2D). Tumor
growth inhibition at 20 mg/kg was 119% for KARPAS-299 and
104% for NB-1 on day 20. Thus, CH5424802 has a potent ther-
apeutic efficacy against tumors with genetic alterations of ALK
in vivo.
To clarify the downstream signal pathway of EML4-ALK in
NSCLC, we performed Affymetrix GeneChip analysis using
CH5424802-treated NCI-H2228 xenograft tumors and compre-
hensively characterized the gene expression regulated by
inhibition of activated ALK. The majority of genes commonly
downregulated by treatment with CH5424802 were regulated
by STAT3 (Table 2). There was not much difference between 4
and 20 mg/kg on genes downregulated by CH5424802. To vali-
date the microarray data, we conducted real-time quantitative
polymerase chain reaction (PCR) and confirmed a significant
decrease in the expression of STAT3 target genes, such as
BCL3, NNMT, SOCS3, and BCL2L1, in CH5424802-treated
NCI-H2228 xenograft tumors (Figure 3A). Consistent with these
results, CH5424802 suppressed the phosphorylation of STAT3
in a dose-dependent manner (2–20 mg/kg) (Figure 3B). A partial
decrease in AKT phosphorylation was also observed in
CH5424802-treated xenograft tumors.
Previous reports have demonstrated that STAT3 is required for
ALK-mediated lymphomagenesis in ALCL (Chiarle et al., 2005).
In the ALK-positive ALCL cell line KARPAS-299, we confirmed
that CH5424802 completely inhibited the phosphorylation of
STAT3 at Tyr705 (Figure S2A). Furthermore, the single knock-
down of STAT3 as well as ALK by siRNA led to a significant inhi-
bition in cell growth (Figure S2B), suggesting that the STAT3
pathway would be critical for NPM-ALK signaling in ALCL. In
contrast the growth of NCI-H2228 NSCLC cells expressing
EML4-ALK was not affected by treatment of STAT3 siRNA682 Cancer Cell 19, 679–690, May 17, 2011 ª2011 Elsevier Inc.(Figure S2C). STAT3 activation is mediated through the Janus
family kinases (JAK), which include four family members:
JAK1, JAK2, JAK3, and TYK2 (Leonard and O’Shea, 1998). We
also investigated the involvement of JAK1 and TYK2, upstream
of STAT3 in NCI-H2228 cell growth, because NCI-H2228 cells
do not express the other molecules, i.e., JAK2 and JAK3.
However, single knockdown of either JAK1 or TYK1 did not
cause a significant change in the cell viability of NCI-H2228,
and similar results were observed in single knockdowns of
AKT1, ERK1, and ERK2 (Figure S2C).
Potency of CH5424802 against the L1196M Gatekeeper
Mutation of ALK
The point mutations in the kinase domain are known as one of
themechanisms of acquired resistance to small-molecule kinase
inhibitors. In particular the gatekeeper mutations, such as
T790M in EGFR and T351I in ABL, are one of the most frequent
causes of resistance. The sequence analysis of the gatekeeper
region in the kinase domain revealed that L1196 of ALK corre-
sponded to the gatekeeper residue (Figure 4A). A recent study
using the gatekeeper mutant of NPM-ALK by a single nucleotide
change showed that only L1196M, involving a substitution of
methionine for leucine at position 1196 in ALK, exhibited
increased kinase activity as compared with wild-type ALK (Lu
et al., 2009). In contrast the substitution of arginine, proline,
glutamine, or valine presented nondetectable or weaker kinase
activity in cells. To evaluate the inhibitory effect of CH5424802
on the most predictable resistant mutation L1196M of ALK, we
calculated the inhibitor constant (Ki) of CH5424802 or PF-
02341066 using recombinant glutathione S-transferase (GST)-
fused ALK and the mutant L1196M protein. CH5424802 had
substantial inhibitory potency against both native ALK (Ki =
0.83 nM) and L1196M (Ki = 1.56 nM). In contrast the affinity of
PF-02341066 for L1196M was found to be more than 10-fold
weaker than that for the wild-type (Figures 4B; Figure S3A). To
explore the effect of L1196M-driven cell growth on both
compounds, we generated multiple stable transformants of
Ba/F3 cells expressing EML4-ALK (variant 1) and the mutant
L1196M (Figure 4C). CH5424802 showed a higher sensitivity
against both native EML4-ALK and EML4-ALK L1196M-driven
Ba/F3 cell clones grown in the absence of IL-3, as compared
with the IL-3-dependent, EML4-ALK-independent Ba/F3
parental cells (Figures 4D; Figure S3B). Moreover, the sensitiv-
ities of L1196M-driven Ba/F3 cell clones to PF-02341066 were
lower, closely resembling that of the Ba/F3 parental cells. The
therapeutic indexes of CH5424802 and PF-02341066, the IC50
ratio of EML4-ALK L1196M-driven cell clones to the parental
cells, were 7- to 12-fold and 1- to 2-fold. To confirm target inhi-
bition of CH5424802 in each cell line, we tested the effect of
CH5424802 on the phosphorylation of EML4-ALK. Consistent
with the results of cell growth inhibition, CH5424802 could block
cellular phosphorylation of ALK against both native EML4-ALK
and the L1196M mutant in a concentration-dependent manner
(Figure 4E).
The EML4-ALK C1156Y and L1196M mutations were recently
identified in a pleural-effusion specimen from a patient with
NSCLC who relapsed after a partial response to PF-02341066
(Choi et al., 2010). Therefore, we examined the inhibition of
ALK C1156Y both in the cell-free ALK enzyme assay with
Figure 2. Antitumor Activity of CH5424802 in Mouse Xenograft Model of NSCLC
(A) Mice bearing NCI-H2228 and A549 were administered CH5424802 orally once daily for 11 days (NCI-H2228, days 18–28; A549, days 27–37) at the indicated
doses. Tumor volume and body weight change for each dose group were measured. Data are shown as mean ± SD (n = 4–5). Parametric Dunnett’s test:
***p < 0.001; N.S., not significant, versus vehicle treatment at final day.
(B) Mice bearing NCI-H2228 cells were orally administered a single dose of 0 (vehicle) or 20 mg/kg of CH5424802, and xenograft tumors were extracted at 4 hr
post-dosing, fixed in formalin, and embedded in paraffin. Treated samples were immunostained for phospho-ALK (Tyr 1604). Scale bar, 100 mm.
(C) Mice bearing NCI-H2228 cells were administered CH5424802 orally once daily at 60 mg/kg for 3 weeks (days 27–47). Then tumor volume (mean ± SD) was
continuously measured during the treatment and drug-free period for 4 weeks. Data are shown as mean ± SD (n = 5).
(D) Mice bearing KARPAS-299 and NB-1 were administered CH5424802 orally once daily for 11 days (days 10–20) at the indicated doses. Tumor volume for each
dose group was measured. Data are shown as mean ± SD (n = 4–5). Parametric Dunnett’s test: ***p < 0.001, versus vehicle treatment at final day.
See also Table S4.
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CH5424802 Can Block Gatekeeper Mutant of ALKGST-ALK C1156Y and a cell proliferation assay with Ba/F3 ex-
pressing EML4-ALK C1156Y. The in vitro enzyme inhibitory
activity of CH5424802 to C1156Y was similar to that to wild-
type ALK, whereas PF-02341066 showed slightly weaker inhibi-
tion (Figure S3A). Consistently, CH5424802 was effective
against C1156Y-driven Ba/F3 cells, and the parent/EML4-ALK
C1156Y IC50 ratio of CH5424802 was higher than that of
PF-02341066 (20- to 33-fold versus 3- to 5-fold) (Figure S3B,
lower panel). In addition to L1196M and C1156Y, F1174L
mutation was identified as one of the causes of PF-02341066
resistance in a patient with an IMT harboring an RANBP2-ALK
translocation who had progression while on PF-02341066
(Sasaki et al., 2010). We confirmed the inhibitory potency of
CH5424802 to F1174L in both a cell-free kinase assay and an
antiproliferative assay using the neuroblastoma KELLY cell line
that expresses F1174L (Table S2). The inhibitory activity in vitro
to F1174L (IC50 = 1.0 nM) was comparable to that to wild-type
ALK (Table 1).To further assess the in vivo antitumor activity of CH5424802
against L1196M-driven tumors, we used xenograft models of
Ba/F3 expressing native EML4-ALK (clone #10) and the mutant
L1196M (clone #303). We showed that administration of
CH5424802 led to significant tumor regression against both
native EML4-ALK- and L1196M-driven tumors (Figure 5). On
the other hand, PF-02341066 (100 mg/kg) resulted in no signifi-
cant tumor growth inhibition against L1196M-driven tumors.
Furthermore, we confirmed that phospho-STAT3, one of the
downstream targets of ALK, was abolished in both tumors that
were treated with CH5424802 (Figure 5).
In recent studies, X-ray crystal structures of the ALK cata-
lytic domain have been determined in the apo, ADP-, and
kinase inhibitor-bound forms (Lee et al., 2010; Bossi et al.,
2010). To understand the binding mode of CH5424802 with
the ALK protein, we also determined the crystal structure of
the human ALK and CH5424802 complex, and confirmed
that CH5424802 binds to the ATP site of ALK in the DFG-inCancer Cell 19, 679–690, May 17, 2011 ª2011 Elsevier Inc. 683
Table 2. Downregulated Differentially Expressed Genes in CH5424802-Treated NCI-H2228 Xenograft Tumors
Probe ID Gene
Mean Fold Change
(versus vehicle)
Reported STAT3 Regulation Reference4 mg/kg 20 mg/kg
222088_s_at SLC2A3 0.21 0.19 + Dauer et al. (2005)
204908_s_at BCL3 0.24 0.19 + Dauer et al. (2005)
206697_s_at HP 0.29 0.31 + Zauberman et al. (2001)
209122_at ADFP 0.30 0.23 – –
202498_s_at SLC2A3 0.32 0.32 + Dauer et al. (2005)
208470_s_at HP 0.33 0.33 + Zauberman et al. (2001)
202237_at NNMT 0.35 0.20 + Tomida et al. (2008)
202912_at ADM 0.39 0.43 + Dauer et al. (2005)
211906_s_at SERPINB4 0.39 0.32 + Dauer et al. (2005)
201170_s_at BHLHB2 0.41 0.22 – –
Mice bearing NCI-H2228 cells were orally administered a dose of 0 (vehicle), 4, or 20mg/kg of CH5424802, and the tumors were collected and lysed at
6 hr post-dose. Total RNA was extracted from xenograft tumors. Mean fold changes of duplicates identified by microarray compared to vehicle treat-
ment are shown. Significantly (p < 0.05) common downregulated genes in both 4 and 20 mg/kg CH5424802-treated xenograft tumors were selected,
and the top ten in 4 mg/kg are listed.
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CH5424802 Can Block Gatekeeper Mutant of ALKmode (Figures 6A and 6B). Carbonyl oxygen on the 11 posi-
tion of the benzo[b]carbazole moiety of CH5424802 forms
a crucial hydrogen bond with the backbone NH of Met1199
in the hinge region. Moreover, other hydrogen bonds are
also formed with the NH group on 5 position and the cyano
group on 3 position, which are embedded in a hydrogen-
bonding network via the solute ethylene glycol and/or water
molecules, to the neighboring amino acids Lys1150,
Glu1167, Gly1269, Glu1270, and Arg1253 (Figure 6C). Another
remarkable feature found in the CH5424802-ALK complex is
a hydrophobic interaction, such as the CH/p hydrogen
bond. The benzo[b]carbazole moiety of CH5424802 is posi-Figure 3. Downstream Signaling Pathway in NCI-H2228 Cells Harborin
(A) Mice bearing NCI-H2228 cells were orally administered CH5424802 at 6 mg/k
each transcript were measured by quantitative RT-PCR. Data are shown as mean
treatment.
(B) Mice bearing NCI-H2228 cells were orally administered CH5424802 at 0, 0.6, 2
STAT3, phosphorylated STAT3 (Tyr 705), AKT, phosphorylated AKT (Ser 473)
immunoblot analysis using antibodies against each of them.
See also Figure S2.
684 Cancer Cell 19, 679–690, May 17, 2011 ª2011 Elsevier Inc.tioned in the flat pocket (ATP-binding site) between the N-
and C-lobes, of which the amino acid residues are hydro-
phobic. Leu1196 in N-lobe is close to the carbon atom of
cyano group, and the distance between them is 3.57 A˚, indi-
cating an efficient CH/p interaction. However, no productive
interaction was noted between PF-02341066 and Leu1196
(Figure 6D). An in silico modeling study suggested that
CH5424802 could maintain the hydrogen-bonding network
around cyano group; furthermore, the carbon atom of the
cyano group could have a CH/p interaction with the CG atom-
of the Met1196 instead of Leu1196 even in the L1196M-
mutated model based on the crystal structures (data notg EML4-ALK
g, and the tumors were collected and lysed at 6 hr post-dosing. The levels of
± SD (n = 3). Student’s t test: *p < 0.05, **p < 0.01, ***p < 0.001, versus vehicle
, 6, or 20 mg/kg, and the tumors were collected and lysed at 4 hr post-dosing.
, ERK1/2, and phosphorylated ERK1/2 (Thr 202/Tyr 204) were detected by
Figure 4. Blockade of CH5424802 against the L1196M Gatekeeper Mutation of ALK
(A) Alignment of sequences around the gatekeeper regions of ALK and other protein tyrosine kinases. The amino acid sequences around the gatekeeper region of
ALK, ABL, EGFR, and KIT were compared.
(B) In vitro kinase inhibitory assays of ALK (amino acids 1081–1410) or the L1196M mutant fused to GST in the presence of CH5424802 or PF-02341066 were
carried out. The Ki values were determined graphically from Dixon plots. Data are shown as geometric mean ± SD of three independent experiments.
(C) Ba/F3 cells were stably transfected with pcDNA3.1/hygro-EML4-ALK and the L1196Mmutant. The expressions of p-ALK, ALK, and actin in each clone were
detected by immunoblot analysis.
(D) Ba/F3 cells grown in the presence of IL-3, or Ba/F3 cells expressing native EML4-ALK (clone #2, #10, #101, and #155) and EML4-ALK L1196M (clone #216,
#302, #303, and #355), were treated with CH5424802 or PF-02341066 for 48 hr, and then the viable cells were measured by the CellTiter-Glo Luminescent Cell
Viability Assay. IC50 values were determined by plotting the drug concentration versus percentage of cell growth inhibition. Data are shown as mean ± SD (n = 3).
(E) Ba/F3 cells, expressing native EML4-ALK (clone #10) and EML4-ALK L1196M (clone #303), were treated with the indicated concentrations of CH5424802 or
100 nM PF-02341066 for 2 hr. The levels of ALK and phosphor-ALK (Tyr 1604) were detected by immunoblot analysis using antibodies against each of them.
See also Figure S3.
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CH5424802 against L1196M mutation as confirmed by biolog-
ical assay (Figure 4B).
DISCUSSION
CH5424802 (development code: AF802) is currently being
investigated in phase I/II clinical trials for patients with ALK-
positive NSCLC (JAPIC ID JapicCTI-101264). A remarkable
characteristic of CH5424802 is the high selectivity for ALK
among various types of kinases, including c-MET and INSR.
Kinase selectivity of a compound is related to the number of
hinge hydrogen bonds with the kinase inhibitor. Most of the
approved kinase inhibitors, such as erlotinib, imatinib, and lapa-
tinib, form only one hydrogen bond with the hinge region
(Ghose et al., 2008). Crystal structural analysis revealed that
CH5424802 has one hinge hydrogen bond with the backbone
of NH of Met1199 (Figure 6C), whereas other ALK inhibitors,
PF-02341066, NVP-TAE684, and PHA-E429, form two or three
hinge hydrogen bonds (PDB IDs 2XP2, 2XB7, and 2XBA), sug-gesting that our benzo[b]carbazole derivative may be beneficial
in achieving higher selectivity for ALK.
A c-MET/ALK inhibitor PF-02341066 is effective against
advanced NSCLC carrying activated ALK (Kwak et al., 2010).
The grade 3 or 4 adverse events for PF-02341066 in clinical
development consist mostly of ALT and AST elevations (6%
each); however, to our knowledge, the precise mechanism
remains unknown. NVP-TAE684 suppresses cellular prolifera-
tion of an NPM-ALK fusion kinase-dependent cell line (Galkin
et al., 2007). Although the IC50 of INSR was 10–20 nM in an
in vitro enzyme assay, this was not consistent with cellular
INSR activity in H-4-II-E rat hepatoma cells. Also, NVP-TAE684
is preferentially efficacious to not only ALK-dependent cell lines
but also the neuroblastoma cell lines without obvious ALK gene
alterations, implicating IGF-IR as a potential target (McDermott
et al., 2008). Furthermore, the chronic inhibition of IGF-1R/
INSR results in sustained hyperinsulinemia in mice using another
ALK inhibitor, GSK1838705A (Sabbatini et al., 2009). Because
ALK expression in normal adult tissues is limited to very low
levels, selective ALK inhibitors would exhibit sufficiently wideCancer Cell 19, 679–690, May 17, 2011 ª2011 Elsevier Inc. 685
Figure 5. Efficacy in Mice Models of Native
EML4-ALK and EML4-ALK L1196M-Driven
Tumors
Mice bearing Ba/F3-EML4-ALK (clone #10) and
EML4-ALK L1196M (clone #303) were adminis-
tered vehicle, CH5424802 (60 mg/kg), or
PF-02341066 (100 mg/kg) orally once daily for
8 days. Tumor volume for each dose group was
measured. Data are shown as mean ± SD (n = 5).
Parametric Dunnett’s test: ***p < 0.001; N.S., not
significant, versus vehicle treatment at final day.
For pharmacodynamic assay, mice bearing
Ba/F3-EML4-ALK (clone #10) and -EML4-ALK
L1196M (clone #303) were orally administered at
single dose of vehicle, CH5424802 (60 mg/kg), or
PF-02341066 (100 mg/kg), and the tumors were
collected and lysed at 4 hr post-dosing. STAT3
and phosphorylated STAT3 (Tyr 705) were de-
tected by immunoblot analysis using antibodies
against each of them (n = 2 per group).
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CH5424802 Can Block Gatekeeper Mutant of ALKtherapeutic windows in patients with ALK-activated cancers. We
expect that CH5424802 with ALK selectivity could provide
a higher exposure than that of the efficacious dose, leading to
greater efficacy in clinic.
CH5424802 showed a potent efficacy against ALK-addicted
tumors, such as NSCLC expressing EML4-ALK, ALCL express-
ing NPM-ALK, and ALK-amplified neuroblastoma, in vitro and
in vivo. Furthermore, we found that CH5424802 could induce
caspase-3/7 activation in spheroids with in vitro 3D tissue struc-686 Cancer Cell 19, 679–690, May 17, 2011 ª2011 Elsevier Inc.ture that mimics in vivo tumors (Figure 1E), suggesting that the
ability to induce apoptosis by ALK inhibition might be reflected
in strong tumor regression. We examined the change in the
gene expression or signal transduction of xenografted tumors
expressing EML4-ALK protein and confirmed the suppression
of the STAT3 pathway following treatment with CH5424802.
The STAT3 target genes, such as BCL3 and NNMT, as well as
phospho-ALK and -STAT3 might be useful pharmacodynamic
markers for the clinical evaluation of ALK inhibitors. However,Figure 6. X-ray Structure of the ALK and
CH5424802 Complex
(A) Chemical structure of CH5424802. The posi-
tions of substituents are numbered.
(B) Overall structure of ALK containing
CH5424802 shown as a cartoon diagram in light
blue (PDB ID 3AOX). CH5424802 is shown as
a stick model, colored by element type (C in green,
O in red, and N in blue). L1196 residue is shown as
a space-filling model, colored by element type as
the ligand except C in white.
(C) Interaction of CH5424802 with ALK at the ATP-
binding site. Solvent water molecules forming
a hydrogen-bonding network with the ligand are
depicted within red small spheres. An ethylene
glycol (cryosolvent) and amino acid residues,
which form hydrogen bonds to the ligand directly
or via water molecules, are depicted as stick
models colored in the same manner as (B).
(D) Superposition of CH5424802-hALK and
PF-02341066-hALK (PDB ID 2XP2). The super-
position was based on the Ca positions of the
two complexes. Protein cartoon diagrams of
CH5424802 complex are in light blue, and PF-
02341066 is in pale yellow. PF-02341066molecule
as a stick model (C in pink) is overlaid on
CH5424802. In each complex, L1196 is shown as
a stick model.
See also Table S5.
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NSCLC cells remain unknown. The growth of NCI-H2228NSCLC
cells expressing EML4-ALKwas not affected in the single knock-
down of gene including STAT3 (Figure S2C), although the STAT3
pathway is critical for the growth of ALCL cells expressing NPM-
ALK (Figure S2B) (Chiarle et al., 2005). A recent report showed
that overexpression of EML4-ALK variant 3 in 293T cells resulted
in increased phosphorylation of STAT3, AKT, and ERK1/2,
whereas enhanced phosphorylation of ERK1/2 was not promi-
nent in COS-7 cells (Wong et al., 2011). In our studies treatment
of CH5424802 in NCI-H2228 led to the reduction of both phos-
pho-STAT3 and phospho-AKT (Figure 1B). Unlike proliferation
of NPM-ALK-positive cells, that of EML4-ALK-positive cells
might require combined multiple downstream signaling path-
ways, but not a single pathway. The subcellular localization of
ALK fusion proteins likely depends on the fusion partner. NPM-
ALK in ALCL is present in both the nucleus and cytoplasm,
whereas EML4-ALK in NSCLC has been detected in the cyto-
plasm, but not in the nucleus (Takeuchi et al., 2009). From these
observations the downstream pathway of ALK appears to
depend on the fusion partners and cell types. Further detailed
studies are needed to elucidate the downstream signal of
EML4-ALK in NSCLC to explore options for combination therapy
based on clinical rationale.
In order to verify the potency to combat resistance to ALK
inhibitors, we first focused on the gatekeeper mutation because
it is one of the most frequently reported mutants commonly
occurring in clinical kinase inhibitor resistance and is located
next to the ATP-binding region. Gatekeeper mutations in
EGFR,ABL, orKIT are involved in the resistance to certain kinase
inhibitors used clinically (Branford et al., 2002; Pao et al., 2005;
Tamborini et al., 2004). In this study we confirmed that
CH5424802 displayed substantial efficacy against gatekeeper
mutant L1196M-driven tumors in vivo, despite a slightly weaker
affinity of CH5424802 for L1196M as compared to native ALK. In
the in vitro experiments using Ba/F3 expressing EML4-ALK or
the mutant L1196M, the IC50 ratio of CH5424802 in L1196M (7-
to 12-fold) was similar to that of PF-02341066 in native
EML4-ALK (8- to 13-fold) (Figure S3B), which is clinically effec-
tive. The efficacy of CH5424802 would be insusceptible to differ-
ences in subtle affinity caused by single amino acid changes
such as L1196M, compared with that of PF-02341066, because
CH5424802 has a higher IC50 ratio in Ba/F3 expressing native
EML4-ALK than PF-02341066 (33- to 52-fold versus 8- to
13-fold) (Figure S3B). On the other hand, in L1196M-driven
Ba/F3 cells, the IC50 ratio of PF-02341066 was 1- to 2-fold,
and consistently, L1196M-driven Ba/F3 tumors showed resis-
tance to PF-02341066 (100mg/kg qd) in vivo (Figure 5). In clinical
pharmacokinetics of PF-02341066 (250 mg bid) at MTD/RP2D,
the median trough plasma concentration at steady state was
274 ng/ml (Tan et al., 2010, J. Clin. Oncol., abstract), and at
this exposure level, PF-02341066 was effective against ALK-
positive NSCLC. In our experiments after repeated qd dosing
of 100 mg/kg PF-02341066 in mice, the mean plasma levels
reached 2800, 989, and 899 ng/ml at 2, 7, and 24 hr, respectively,
and thus, a sufficiently higher exposure was achieved in mice
than by the clinical dose.
In a previous study an irreversible EGFR kinase inhibitor, such
as neratinib (HKI-272), provided the ability to inhibit gatekeepermutations of EGFR; however, the clinical efficacy of these inhib-
itors has been limited (Sequist et al., 2010). This clinical result
would be due to toxicities of neratinib associated with wild-
type EGFR inhibition, such as diarrhea and rash, demonstrating
the need for mutant-selective kinase inhibitors (Zhou et al.,
2009). On the other hand, in the case of ALK inhibitors, the effect
of on-target toxicity by inhibition of wild-type ALK would be less
because ALK expression in normal tissues is restricted, and
ALK-deficient mice revealed no obvious abnormalities in any
tissue (Bilsland et al., 2008), and in clinical trial of PF-
02341066, on-target toxicity of ALK has not been clarified yet.
Additionally, in the case of potent BCR-ABL inhibitor dasatinib,
although E255K, L248V, and G250E in BCR-ABL were 4.45- to
5.61-fold less sensitive to dasatinib than the wild-type in
a BCR-ABL-transfected Ba/F3 cell system (Redaelli et al.,
2009), a favorable response rate was achieved in patients with
these imatinib-resistant mutations in clinic (Mu¨ller et al., 2009).
A key determinant of clinical efficacy to drug would depend on
the therapeutic window between efficacy and safety.
The difference in sensitivity to the compound between native
ALK and the mutant L1196M in Ba/F3 cells was slightly greater
than that in a cell-free enzyme assay. For native ALK and ALK
1196M, the KM values for ATP were 34 and 25 mM, respectively,
in our kinase assay. The difference in this ATP affinity might be
slightly reflected in the sensitivity in Ba/F3 cells.
We expect that CH5424802 might provide therapeutic oppor-
tunities for patients with acquired resistance to PF-02340166. In
order to elucidate alternative acquired resistant mechanisms
(e.g., amplification of other oncogenes), further genetic analyses
are needed for the patients with resistance to ALK inhibitors.
EXPERIMENTAL PROCEDURES
Compounds and Cell Lines
CH5424802,9-ethyl-6,6-dimethyl-8-[4-(morpholin-4-yl)piperidin-1-yl]-11-oxo-
6,11-dihydro-5H-benzo [b]carbazole-3-carbonitrile hydrochloride, was
synthesized at Chugai Pharmaceutical Co., Ltd., according to the procedure
described in WO2010143664. PF-02341066 was purchased from Selleck
Chemicals or synthesized according to the procedure described in
WO2006021884. Cell lines were obtained from American Type Culture Collec-
tion (ATCC) or RIKEN. Each cell linewas cultured using themedium recommen-
ded by the suppliers.
Kinase Inhibitory Assays In Vitro
Protein kinases were purchased from Carna Biosciences or Millipore Corpora-
tion. The inhibitory ability against each kinase except for MEK1 and Raf-1 was
evaluated by examining their ability to phosphorylate various substrate
peptides in the presence of CH5424802 using time-resolved fluorescence
resonance energy transfer (TR-FRET) assay or fluorescence polarization (FP)
assay (details of assay conditions for each kinase are available in Table S1).
The inhibitory activity against MEK1 was evaluated by quantitative analysis
of the phosphorylation of a substrate peptide by a recombinant ERK2 protein
in the presence of CH5424802. The inhibitory activity against Raf-1 was eval-
uated by examining the ability of the kinases to phosphorylate MEK1 in the
presence of CH5424802.
Immunoblotting and Immunoprecipitation
Cells were lysed in Cell Lysis Buffer (Cell Signaling Technology) containing
1mMPMSF, 1% (v/v) phosphate inhibitor cocktail 1, 1% (v/v) phosphate inhib-
itor cocktail 2, and Complete Mini, EDTA-Free 1 (Roche). Cell lysates were
subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis
(SDS-PAGE), and the separated proteins were electrophoretically transferred
to Immobilon-Pmembranes (Millipore). After blocking in BlockingOne (NacalaiCancer Cell 19, 679–690, May 17, 2011 ª2011 Elsevier Inc. 687
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antibodies diluted with anti-ALK (Invitrogen; #51-3900), anti-STAT3, anti-
Phospho-STAT3 (Tyr 705), anti-AKT, anti-Phospho-AKT (Ser 473), anti-p44/
42 MAP Kinase (ERK1/2), anti-Phospho-ERK1/2 (Thr 202/Tyr 204), anti-ALK
(C26G7), anti-Phospho-ALK (Tyr 1604) (Cell Signaling Technology; #3341),
and anti-actin (Sigma). For the detection of phosphorylated ALK in NCI-
H2228 cells, cell lysates were immunoprecipitated with anti-phosphotyrosine
(PY-20) antibody (BD Biosciences). The immunoprecipitants were then
collectedwith ProteinG Sepharose (GEHealthcare) and subjected to immuno-
blot analysis using an anti-ALK antibody. Themembranes were incubated with
an anti-rabbit or anti-mouse IgG, HRP-linked antibody (Cell Signaling Tech-
nology). The bands were detected with ECL Plus (GE Healthcare) followed
by LAS-4000 (Fujifilm).
Cell Growth Inhibition and Caspase-3/7 Assay
Cells were cultured in 96-well plates overnight and incubated with various
concentrations of compound for the indicated time. For spheroid cell growth
inhibition assay, cells were seeded on spheroid plates (Sumilon Celltight
Spheroid 96U; Sumitomo Bakelite Inc.), incubated overnight, and then treated
with compound for the indicated times. The viable cells were measured by the
CellTiter-Glo Luminescent Cell Viability Assay (Promega). Caspase-3/7
assay was evaluated using the Caspase-Glo 3/7 Assay Kit (Promega).
In Vivo Studies
Cell lines were used to evaluate the antitumor activity of CH5424802 in vivo.
They were grown as s.c. tumors in SCID or nude mice (Charles River Labora-
tories). Therapeutic experiments were started (day 0) when the tumor reached
250 or 350 mm3. Mice were randomized to treatment groups to receive
vehicle or CH5424802 (oral, qd) for the indicated duration. Final concentration
of vehicle was 0.02 N HCl, 10% DMSO, 10% Cremophor EL, 15% PEG400,
and 15% HPCD (2-hydroxypropyl-b-cyclodextrin). The length (L) and width
(W) of the tumor mass were measured, and the tumor volume (TV) was calcu-
lated as: TV = (L 3 W2)/2. Tumor growth inhibition was calculated using the
following formula: tumor growth inhibition = [1  (T  T0)/(C  C0)] 3 100,
where T and T0 are the mean tumor volumes on a specific experimental day
and on the first day of treatment, respectively, for the experimental groups
and likewise, where C and C0 are the mean tumor volumes for the control
group. The effective dose for 50% inhibition (ED50) was calculated from the
values of tumor growth inhibition on the final experimental day using XLfit
version 5.1.0.0. The rate of change in body weight (BW) was calculated using
the following formula: BW = W/W0 3 100, where W and W0 are the body
weights on a specific experimental day and on the first day of treatment,
respectively. All animal experiments in this study were performed in accor-
dance with protocols approved by the Institutional Animal Care and Use
Committee (IACUC) of Chugai Pharmaceutical Co., Ltd.
Immunohistochemistry
Xenograft tumors were extracted, fixed in formalin, and embedded in paraffin.
Immunostaining for phosphorylated ALK was performed using phospho-ALK
(Tyr 1604) antibody (Cell Signaling Technology; #3341). Immunohistochem-
istry was performed using the DISCOVERY XT automated staining platform
(Ventana Medical Systems).
Microarray and Quantitative RT-PCR
Total RNA was extracted using the RNeasy kit (QIAGEN), and reverse tran-
scribed, labeled, and hybridized to Human Genome U133 Plus 2.0 arrays
(Affymetrix) according to the manufacturer’s instructions. The expression
value for each probe was calculated using the GC-RMA algorithm. For quan-
titative RT-PCR, RNAwas amplified in QuantiFastMultiplex RT-PCR (QIAGEN)
using a Universal probe library (Roche Applied Science) and the LightCycler
System (Roche). Glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
served as an internal control.
Generation of Recombinant ALK and the Mutant Proteins
To evaluate the in vitro kinase assay of ALK, we generated a GST-tagged,
kinase domain (amino acid 1081–1410) of ALK or the mutants by using
a Bac-to-Bac Baculovirus Expression System (Invitrogen) in Sf-9 insect cells
according to the manufacturer’s protocols. Mutant constructs were generated688 Cancer Cell 19, 679–690, May 17, 2011 ª2011 Elsevier Inc.using the QuikChange Site-Directed Mutagenesis Kit (Stratagene). The cells
were lysed in lysis buffer (phosphate-buffered saline with 0.1% Triton X-100
and Roche Complete protease inhibitors) and centrifuged. Glutathione
Sepharose 4B (GE Healthcare) was incubated for 1 hr with the soluble fraction
of the lysate and washed in buffer A (50 mM Tris-HCl [pH8.0], 150 mM NaCl,
and 1% Triton X-100). The proteins were eluted with elution buffer (50 mM
Tris-HCl [pH8.0], 150 mM NaCl, 0.5% Triton X-100, and 20 mM reduced
L-glutathione). The protein expression and purification were confirmed by
SDS-PAGE.Stable Ba/F3 Transfectants
The EML4-ALK gene (variant 1) and the L1196Mwere inserted into pcDNA3.1/
hygro vector (Invitrogen). EML4-ALK L1196M was generated using the Quik-
Change Site-Directed Mutagenesis Kit (Stratagene) and confirmed by rese-
quencing the whole construct. Ba/F3-EML4-ALK and the L1196M cell lines
were generated by transfecting Ba/F3 cells with pcDNA3.1/hygro-EML4-
ALK and the L1196Mmutant by using the NucleoFector device (Amaxa); stable
transfectants were then isolated from the cultured medium without IL-3.Crystallization and Structural Determination
of ALK-CH5424802 Complex
Protein crystallography was performed by proteros biostructures GmbH
(Martinsried/Munich, Germany). The kinase domain of human ALK (residues
1069–1411) was expressed in SF9 cells with a GST-fusion tag, which was
removed by protease cleavage during purification; the kinase domain was then
purified using affinity, size exclusion, and ion-exchange chromatography. The
purified proteinwas concentrated to20–40mg/ml and stored at80Cuntil use.
Crystals were obtained at 4C from sitting drops using a reservoir solution
(5%–20% PEG 550 MME and 0.1 M maleic acid [pH 5.5]) by vapor diffusion.
The crystals were shock-frozen in liquid nitrogen after the addition of 22% eth-
yleneglycol. Diffraction data were collected at 90 K at beamline X06SA in SLS
using a PILATUS 6M detector (DECTRIS Ltd.). The data set was processed
with XDS and scaled with XSCALE (Kabsch, 1993) in the space group
P212121. The structure of the ALK and CH5424802 complex was determined
by molecular replacement by Phaser (McCoy et al., 2007) with an insulin
receptor kinase (PDB ID 1GAG). The crystals contain one monomer of ALK
in the asymmetric unit. The model was rebuilt manually in Coot (Emsley
et al., 2010), and refined with REFMAC5 (Murshudov et al., 1997) to a final
resolution of 1.75 A˚. B factors were refined isotropically. TLS refinement was
used to improve maps and models. The final model consisted of residues
1086–1401 with three breaks (residues 1124–1127, 1137–1143, 1281–1287
were disordered). The resulting electron density revealed an unambiguous
binding mode of CH5424802. For crystallographic data and refinement statis-
tics, see Table S5.ACCESSION NUMBERS
The atomic coordinates of the ALK-CH5424802 complex structure have been
deposited in the RSCB Protein Data Bank under accession number 3AOX. The
microarray data have been deposited in the GEO database (GEO number:
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